A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery - Trial NCT05872763
Access comprehensive clinical trial information for NCT05872763 through Pure Global AI's free database. This phase not specified trial is sponsored by Hoffmann-La Roche and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 1200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Hoffmann-La Roche
Timeline & Enrollment
N/A
Aug 31, 2023
Jun 30, 2025
Primary Outcome
Median Overall Survival (OS),Median weeks on first-line treatment
Summary
This is a multicenter, observational cohort study in China with both primary prospective data
 collection and retrospective collection of prior treatment information from medical records,
 which enrolls and follows patients who are newly diagnosed with unresectable stage
 IIIB/IIIC/IV Non-Small-Cell Lung Cancer (NSCLC) in the selected sites.
 
 This study aims to describe the clinical practice and long-term survival benefits of patients
 newly diagnosed with unresectable stage IIIB/IIIC/IV NSCLC. The study also seeks to explore
 the condition of biomarker tests utilization, and to assess potential economic impact on
 patients in the real world. The safety related events will also be summarized in this study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05872763
Non-Device Trial